Navigation Links
Cleveland Clinic researchers receive $5 million grant to discover novel pathways to heart disease
Date:7/12/2012

Thursday, July 12, 2012, Cleveland: The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $4.78 million grant to researchers at Cleveland Clinic's Lerner Research Institute to use metabolomics a new approach that focuses on the small-molecule byproducts of metabolism for discovery of novel pathways linked to the development of cardiovascular diseases.

"Despite the identification of numerous genetic and clinical risk factors for cardiovascular disease, we can still only explain in a small fraction of patients why that individual develops the disease; this means many novel pathways contributing to the disease still remain unexplored," said Stanley Hazen, M.D., Ph.D., vice chair of the Lerner Research Institute and section head of Preventive Cardiology & Rehabilitation in the Miller Family Heart and Vascular Institute.

Hazen is co-principal investigator on the study with W.H. Wilson Tang, M.D., director of the Cardiomyopathy Program at Cleveland Clinic, and research director of the Section of Heart Failure and Cardiac Transplantation Medicine in the Miller Family Heart and Vascular Institute.

"By using metabolomics approaches, our goal is to better understand at the molecular-level the mechanisms that cause cardiovascular diseases," said Dr. Tang. "Metabolomics is a powerful discovery platform, and can help lead to improved diagnostics and better treatments to prevent development and progression of cardiovascular disease."

Dr. Hazen and his colleagues' prior research in this area has been successful in discovering new and unexpected pathways involved in heart disease. Last year they identified a dietary nutrient found in animal products that is metabolized by gut flora and linked to atherosclerosis, or the hardening or clogging of the arteries. In a study published in Nature, they found that people are not predisposed to cardiovascular disease solely on their genetic make-up, but also based on how the micro-organisms in their digestive tracts metabolize a specific lipid phosphatidylcholine (also called lecithin). For that discovery, Dr. Hazen and his research team were honored with an inaugural Top 10 Clinical Research Achievement Award from an organization comprised of the nation's most prestigious and acclaimed academic medical centers and other groups.

With the NHLBI grant, Dr. Hazen and his colleagues will extend their research by further analyzing the thousands of metabolites in blood, including many that are formed by gut flora, in order to discover pathways linked to causing heart attacks, strokes, and heart failure. They also propose to manipulate the bacteria in humans, testing whether specific probiotics can play a role in treatment of cardiovascular disease. The research can thus ultimately lead to new treatments, including diets and drugs, for cardiovascular disease as well as improved diagnostics and prevention.

Cleveland Clinic's grant (NHLBI grant number: 1P20HL113452-01) is part of a series awarded by the National Institutes of Health to study the abnormal metabolism of cardiovascular and lung diseases. In addition to Drs. Hazen and Tang, the research team includes co-investigator Zeneng Wang, Ph.D., of Cleveland Clinic; Oliver Fiehn, M.D., of the University of California, Davis; and David Lefer, Ph.D., of Emory University.


'/>"/>

Contact: Wyatt DuBois
duboisw@ccf.org
216-445-9946
Cleveland Clinic
Source:Eurekalert

Related biology news :

1. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
2. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
3. New clinical trial explores novel noninvasive colon cancer screening test
4. Genzyme/ACMG Foundation Genetics Training Award in Clinical Biochemical Genetics announced
5. FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
6. MedNet Solutions to Demonstrate Its Innovative Suite of eClinical Solutions at the 2012 Bio-IT World Conference & Expo
7. Clinical trial launches to see whether vitamin D helps treat multiple sclerosis
8. AAO-HNS releases updated Clinical Indicators
9. Sequencing works in clinical setting to help -- finally -- get a diagnosis
10. VolitionRX Raises Over $1 Million To Begin Clinical Trials of Blood Based Diagnostic Tests
11. Clinical trials for Alzheimers disease preventative drug to begin early 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. ... a free webinar on Performing Quality Investigations: Getting to Root Cause. ... at no charge. , Incomplete investigations are still a major concern to the ...
(Date:6/23/2016)... , June 22, 2016  Amgen (NASDAQ: ... the QB3@953 life sciences incubator to accelerate ... The shared laboratory space at QB3@953 was created to ... key obstacle for many early stage organizations - access ... the sponsorship, Amgen launched two "Amgen Golden Ticket" awards, ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
Breaking Biology Technology: